This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11140%2F14%3A10227295%21RIV15-MSM-11140___/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11140%2F14%3A10227295%21RIV15-MSM-11140___
rdf:type
n6:Vysledek skos:Concept
dcterms:description
Aim: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125 and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. Patients and Methods: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. Results: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females with endometrial cancer 19.0 IU/l, versus healthy females, 15 IU/l. A significant correlation with histopathological disease stage was found for both biomarkers (Spearman correlation). Sensitivity and specificity, and the related cut-off for HE4 suggest that HE4 would be a more appropriate biomarker for differential diagnosis between benign and malignant states. Conclusion: Based on our pilot study, we found that parallel examination of HE4 and CA125 may support endometrial ultrasound finding verification prior to biopsy. This study is ongoing and we expect that results on a larger population may enable HE4 measurement to be implemented in routine practice. Aim: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125 and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. Patients and Methods: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. Results: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females with endometrial cancer 19.0 IU/l, versus healthy females, 15 IU/l. A significant correlation with histopathological disease stage was found for both biomarkers (Spearman correlation). Sensitivity and specificity, and the related cut-off for HE4 suggest that HE4 would be a more appropriate biomarker for differential diagnosis between benign and malignant states. Conclusion: Based on our pilot study, we found that parallel examination of HE4 and CA125 may support endometrial ultrasound finding verification prior to biopsy. This study is ongoing and we expect that results on a larger population may enable HE4 measurement to be implemented in routine practice.
dcterms:title
CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management
skos:prefLabel
CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management
skos:notation
RIV/00216208:11140/14:10227295!RIV15-MSM-11140___
n3:aktivita
n15:I n15:P
n3:aktivity
I, P(EE2.3.20.0040)
n3:cisloPeriodika
1A
n3:dodaniDat
n7:2015
n3:domaciTvurceVysledku
n4:7193467 n4:7725825 n4:8564043 n4:8219303 n4:5209609 n4:4256603 n4:3838463 n4:8873313
n3:druhVysledku
n16:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
6346
n3:idVysledku
RIV/00216208:11140/14:10227295
n3:jazykVysledku
n14:eng
n3:klicovaSlova
HE4; CA125; tumor markers; Endometrial cancer
n3:klicoveSlovo
n9:HE4 n9:Endometrial%20cancer n9:tumor%20markers n9:CA125
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[29D019736DC7]
n3:nazevZdroje
Anticancer Research
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
8
n3:pocetTvurcuVysledku
9
n3:projekt
n18:EE2.3.20.0040
n3:rokUplatneniVysledku
n7:2014
n3:svazekPeriodika
34
n3:tvurceVysledku
Novotný, Zdeněk Vlasák, Pavel Presl, Jiří Topolčan, Ondřej Kučera, Radek Betincová, Lucie Fuchsová, Radka Vrzalová, Jindra Svobodová, Šárka
n3:wos
000329765300044
s:issn
0250-7005
s:numberOfPages
5
n10:organizacniJednotka
11140